AB Science Reports Promising Initial Data from AML Study

AB Science has announced initial positive outcomes from its Phase 1 study on the combination of AB8939 with Venetoclax for treating refractory or relapsed acute myeloid leukemia (AML). The first three patients, all possessing unfavorable genetic profiles, are responding positively to the treatment.

The treatment has been well-received, with no hematological toxicity and a disease control rate of 100%, including one patient achieving complete remission. These promising results emerged after the initial 14-day treatment cycle, even in patients previously unresponsive to Venetoclax combined with other therapies.

This phase of the study will continue to evaluate the treatment's efficacy at higher AB8939 doses, confirming its mechanism of action targeting resistant cancer cells and stem cells. AB Science will hold a virtual conference on October 16 to discuss these findings with noted AML experts.